Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines

Patrick J. Macdonald; Jeffrey M. Schaub; Qiaoqiao Ruan; Carroll L. Williams; John C. Prostko; Sergey Y. Tetin

doi:10.1038/s43856-022-00174-9

Communications Medicine (Aug 2022)

Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines

Patrick J. Macdonald,
Jeffrey M. Schaub,
Qiaoqiao Ruan,
Carroll L. Williams,
John C. Prostko,
Sergey Y. Tetin

Affiliations

Patrick J. Macdonald: Applied Research and Technology, Abbott Diagnostics Division, Abbott Laboratories
Jeffrey M. Schaub: Applied Research and Technology, Abbott Diagnostics Division, Abbott Laboratories
Qiaoqiao Ruan: Applied Research and Technology, Abbott Diagnostics Division, Abbott Laboratories
Carroll L. Williams: Applied Research and Technology, Abbott Diagnostics Division, Abbott Laboratories
John C. Prostko: Applied Research and Technology, Abbott Diagnostics Division, Abbott Laboratories
Sergey Y. Tetin: Applied Research and Technology, Abbott Diagnostics Division, Abbott Laboratories

DOI: https://doi.org/10.1038/s43856-022-00174-9
Journal volume & issue: Vol. 2, no. 1
pp. 1 – 7

Abstract

Read online

Macdonald, Schaub et al. measure apparent antibody affinities to the ACE-2 receptor binding domain of the SARS-CoV-2 spike protein in recipients of the Pfizer, Moderna and J&J vaccines. All vaccinated individuals develop high-affinity antibodies, however the affinities are weaker to Delta and Omicron variants compared to ancestral virus.

Published in Communications Medicine

ISSN: 2730-664X (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://www.nature.com/commsmed/

About the journal